Overview of Hepatitis B, C, and D Epidemiology in Eastern Europe and the Newly Independent States Michael O. Favorov MD, Ph.D., D.Sc. CDC Central Asia.

Slides:



Advertisements
Similar presentations
Integration of Viral Hepatitis Prevention with STD Prevention: What Health Professionals Should Know Presenter: Jay Todd, Training and Public Education.
Advertisements

Predictors of Change in HIV Risk Factors for Adolescents Admitted to Substance Abuse Treatment Passetti, L. L., Garner, B. R., Funk, R., Godley, S. H.,
An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
HIV Risk Behaviors and Alcohol Intoxication among Injection Drug Users in Puerto Rico Tomás D. Matos, MS Center for Addiction Studies Universidad Central.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Hepatitis B: Epidemiology
The HIV/AIDS Epidemic © 2005 John B. Pryor Illinois State University.
Hepatitis C Rapid Antibody Testing Among At-Risk Populations, Arizona, 2014 Felicia McLean Public Health Associate Office for State, Tribal, Local and.
Andrew Waters Regional Epidemiologist Bluegrass Region 2 Hepatitis A Outbreak 2007 ERRT Conference October 2nd, 2007.
HIV Risk Factors and HIV Prevalence Among Street Youth in Russia, Yulia Batluk, HealthRight International.
Iva Pitner Mentor: A. Žmegač Horvat
Hepatitis web study H EPATITIS W EB S TUDY H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School.
Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.
Afghanistan’s Present IDUs-HIV/AIDS Situation and future action plan Dr.Saifur-Rehman NACP Director April,11,2007 Islamic Republic of Afghanistan Ministry.
Hepatitis in a surgeon- problem oriented learning: Part I Paul Froom MD, MOccH Chief of Epidemiology Israel- National Institute of Occupational and Environmental.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
HEPATITIS A VIRUS Week Response Clinical illness ALT IgM IgG HAV in stool Infection Viremia EVENTS IN HEPATITIS A VIRUS INFECTION.
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
Hepatitis C Education & Awareness. Women In Government Women In Government Foundation, Inc. is a national, non-profit, non-partisan organization of women.
Adult Viral Hepatitis Update Roxanne Ereth, MPH, BS Hepatitis C Program Manager Adult Viral Hepatitis Prevention Coordinator.
Hepatitis C- Global and National Perspective Dr Allister Grant Consultant Hepatologist University Hospitals Leicester NHS Trust.
Harold S. Margolis, M.D. Division of Viral Hepatitis
Hepatitis B Virus 28.
State of Hepatitis C- The Nigeria Experience Ghana 12 th August, 2013 Dr. Adegboyega Akere Lecturer/Consultant Physician & Gastroenterologist University.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
Why we are here? However, a general lack of understanding exists among health-care professionals regarding the interpretation of screening test results,
A Cluster of Hepatitis C among Rural, Young Adults – Illinois, 2012 Julia Howland, MPH CPH CDC/CSTE Applied Epidemiology Fellow Illinois Department of.
Grace Van Ness, MPH, CHES, Ann Thomas, MD, MPH & Sharon Vance
Viral Hepatitis Australian Family Physician Vol. 30 No.5, May 2001 Presented by 郭詠怡 Date presented:25/8/2003.
Hepatitis C Testing in the Muslim Community Hasnain Jafferbhoy Grampian Hepatitis Stakeholder Conference 16 th June 2011.
USE OF ACUTE HEPATITIS SURVEILLANCE TO EVALUATE PROGRAM FOR VIRAL HEPATITIS PREVENTION AND CONTROL Central Asian Program, DIH, EPO, CDC.
Enhanced Hepatitis Strain & Surveillance System (EHSSS) in Review BCCDC Hepatitis Site Site Investigator: Liza McGuinness.
21/2/ Viral Hepatitis B (HBV) Associate Professor Family and Community Medicine Department King Saud University.
SEIEVA Integrated Epidemiological System for Acute Viral Hepatitis Alfonso Mele Catania, November
Paradoxes and Problems in Preventing HIV Infection among Injecting Drug Users and Their Sexual Partners in Eastern Europe and Asia Don C. Des Jarlais,
USE OF ACUTE HEPATITIS SURVEILLANCE TO EVALUATE PROGRAM FOR VIRAL HEPATITIS PREVENTION AND CONTROL Central Asian Program, DIH, EPO, CDC.
+ By: Sydney Freedman. + General Background 1895: Germany, smallpox outbreak Led to Jaundice Liver doesn’t destroy blood cells properly 1942: United States,
Hepatitis D (Delta) Virus
Jennifer R. Havens, PhD, MPH Associate Professor
Estimating the Global Burden of HCV Infections Associated with Unsafe Health Care Injections Anja Hauri 1, Gregory Armstrong, 2 Yvan Hutin 1 1. WHO Headquarters,
Hepatitis C Dr R V S N Sarma., M.D Consultant Physician.
HIV Testing in Acute Care Settings Rich Rothman, MD, PhD, FACEP CDC, DHHS, OraSure Technologies, Abbott  Historical.
Prevalence of hepatitis B and C viruses among human immunodeficiency virus infected children in Northern Nigeria. Pennap GRI, Yahuza, AJ and Abdulkarim,
CHRONIC VIRAL HEPATITIS CAUSES. HEPATITIS B Originally known as “serum hepatitis”. Percutaneous inoculation- long been recognized as the route of transmission.
Evaluation of Hepatitis B surveillance system in Armenia, 2014 AUTHORS Karine Gevorgyan Lusine Paronyan Shushan Sargsyan Artavazd Vanyan NCDC, Armenia.
Parallel and Overlapping Prevalence of Hepatitis B and C Viruses in Apparently Healthy Individuals in a Northern Nigerian Population Pennap, GRI and Chuga,
Abstract Problem Statement: As in many former socialist economies, anecdotal reports suggested that injections were overused to administer medications.
High HIV, HBV and HCV Prevalence among People Who Inject Drugs: Results from the First Integrated Bio-behavioral Survey of PWID in Mozambique Authors:
| Web: The findings and conclusions in this report are those of the authors and do not necessarily represent the official.
Readiness To Change HIV/HCV Risk Behavior Among Young African American IDUs. Edward V Morse, PhD, Tulane University Health Sciences Center, Department.
Hepatitis A, B, C: Overview, Serologies, and Vaccination Connie Tien June 6, 2016.
Viral Hepatitis.
Epidemiology of hepatitis B in Ireland Last updated March 2017
Hepatitis C.
By: DR.Abeer Omran Consultant pediatric infectious disease
Seroprevalence of Hepatitis B and C Markers among Inmates Entering the Nevada State Correctional System National Hepatitis Coordinators’ Conference, San.
Pengjun Lu, PhD, MPH;1 Kathy Byrd, MD, MPH;2
Blinded Hepatitis C Antibody Serosurvey among clients using the Wisconsin HIV Counseling, Testing, and Referral Program Angela Russell, MS John Pfister,
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
Hepatitis Primary Care: Clinics in Office Practice
Division of Viral Hepatitis
Hepatitis B Vaccination Assessment Adults Aged Years National Health Interview Survey, 2000 Gary L. Euler, DrPH1, Hussain Yusuf, MBBS2, Shannon.
By: Antehun Alemayehu (M.Sc)
Progress in Facilitating National HCV Prevention
CLINICAL SOLVING PROBLEM
Assessment of risk factors for hepatocellular carcinoma in HIV care and treatment programs across 31 countries: a cross-sectional survey within IeDEA C.
Presentation transcript:

Overview of Hepatitis B, C, and D Epidemiology in Eastern Europe and the Newly Independent States Michael O. Favorov MD, Ph.D., D.Sc. CDC Central Asia Program Director Elena Klimova MD, Ph.D. Moscow Medical and Dentistry School, Infection Disease Department, Associate Professor

Background High risk among intravenous drug users for Viral Hepatitis and HIV infection transmission has been demonstrated worldwide. Limited studies suggest significant changes in risk factors for viral hepatitis B, C, and Delta transmission occurred in the region during the last decade. Descriptive nature of epidemiological studies of risk factors for parenterally transmitted hepatitis in the region. Moldova study (Y. Hutin et al.,1993) – nosocomial transitions main risk factor for HBV infection.

Study Objective To assess risk factors for Viral Hepatitis in hospitalized adult patients and in a reference group in Moscow, Russia.

Methods Study Population Cases – patients with jaundice and ALT elevation (> 5 times higher than normal) hospitalized at Infectious Disease Hospital Number 1 in Moscow, February– May,1998. N = 430. Assessment of patient risk factors by collection of detailed information on: history of injection practices, medical procedures, drug abuse, sexual behavior, alcohol consumption; demographic and other characteristics. N = 300. Reference group (Non-Sick) -- Volunteers from Medical High School and Pre-recruitment medical examination participants, with no history of jaundice. Collected April– June N=311.

Methods Data and Specimen Collection Obtained informed consent. Questionnaire administered. Obtained blood specimens: –blood samples (5cc) drawn using disposable sterile materials (needles, syringes, tubes); –Sera separated by centrifugation and storage at -20 o C until shipment to CDC. ID-linked questionnaire, blood and serum tubes.

Methods Specimens test site - CDC Hepatitis Reference Laboratory EIA Abbott ( North Chicago) –IgM Anti HAV –HBsAg –IgM anti - HBc –Anti-HCV –Anti-HCV Confirmatory test. –Anti HDV (total) Mosaic protein test (CDC) –Anti HEV (IgG and IgM)

Study Population: Demographics and Education Percent in Study Groups

Age distributions by group Numbers Cases Group Mean Age = /-9.7 years (Median = 21) Comparison Group Mean Age = /-2.3 years (Median = 19)

Etiology of Viral Hepatitis in Non-epidemic Season (February – May, 1998) 10% 63.7% 0.3% 14% 8% 4% Number of Patients N=430

Combined Viral Hepatitis Risk Factors among HBV, HCV Patients and Comparison Group HBV-Control: OR= 10.8 (95% CI ) P < HCV-Control: OR= 12.9 (95% CI ) P <

Parenteral Exposure among HBV, HCV Patients and Comparison Group P < 0.001

Blood Transfusion among HBV, HCV Patients and Comparison Group P > 0.26

At Least One Night in the Hospital among HBV, HCV Patients and Comparison Group P to contn.<0.01 P to contn.> 0..6

At Least One Visit to Ambulatory with Parenteral Exposure among HBV, HCV Patients and Comparison Group P to contn.< P to contn.= 1.0

At Least One Visit to the Dentists with Parenteral Exposure among HBV, HCV Patients and Comparison Group P to contn.< P 1-2 > 0.1

Illicit Drug Use among HBV, HCV Patients and Comparison Group P < 0.001

Illicit Drug Use among HBV, HCV Patients and Comparison Group ( Blood transfusion, Hospitalization, Dentist and Ambulatory Treatment Excluded) P < 0.001

Illicit Drug Use History among HBV, HCV Patients and Comparison Group

Number of Sexual Partners (last 6 month) among HBV, HCV Patients and Comparison Group (other risk factors excluded) P > 0.8

Selected Risk Factors Population Attributable Risk for HBV/HCV patients in Moscow Russia, Risk FactorsHBV N=274 HCV N=62 Illicit Drug Abuse79%87% Outpatient treatment39%34% Dentists14%n.a.** Hospitalization12%8% Tattoo4%n.a. 10 and more sexual partners (last 6 month) 3%n.a. History of Syphilis12%n.a. * - mutual exclusion; ** - Not applicable *

Injections Associated Population Attributable Risk for Acute Hepatitis B Patients (Drug Use Excluded) StudyHBV Moldova, 1993 (Y. Hutin)48% Kazakhstan, 1998 (A. Kazdirbekov) 52% Moscow, %

Conclusions Injection drug use with unsafe injection practice strongly associated with acquiring acute hepatitis B and C in Moscow. Outpatients treatment remain highly associated with acquiring acute hepatitis; attributable risk for non-drug users HBV patients 39%, HCV 34%. Hospitalization, tattooing, multiple sexual contacts demonstrated attributable risk for non-drug users 3 – 12%.

Recommendations Promote the use of single use syringes and needles (auto-disable) in Moscow Promote infection control practices in drug use communities in Moscow Educate drug use communities members and health care workers about the risks associated with re-use injection material

Limitations Control group selection

Acknowledgements Moscow Medical and Dentistry School -N.D. Uschuk -M.M. Gadzhikulieva CDC, Hepatitis Branch -M. Purdy -H. Margolis